Compare General Motors Company (GM) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Motors Company vs Pfizer Inc — how do they compare? General Motors Company trades at $82.6 (market cap $72.17B), while Pfizer Inc trades at $27.95 (market cap $158.56B). The key difference: Pfizer Inc is far larger — about 2.2× General Motors Company's market cap, and Pfizer Inc pays the higher dividend (6.18%). Which is the better fit depends on your goals — on Pluang, investors hold General Motors Company for 83 Days and Pfizer Inc for 158 Days on average.
| GM | PFE | |
|---|---|---|
Market Cap | $72.17B | $158.56B |
Volume | 4,900,304 | 44,138,282 |
Sector | Consumer Cyclical | Health |
52-Week High | $90.30 | $29.02 |
52-Week Low | $55.35 | $23.67 |
Typical Hold Time | 83 Days | 158 Days |
Enterprise Value | $175.15B | $210.06B |
Dividend Yield | 0.88% | 6.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Motors (GM) trades at $80.99, down 1.24% amid broader auto sector weakness. The stock shows mixed signals with bearish technical indicators but strong analyst support (66.7% buy rating) and a $102.08 consensus price target. Recent Q3 2026 sales declined 5.5% due to EV weakness and discontinued models, though the company has beaten earnings estimates for three consecutive quarters. GM benefits from regulatory savings of $20.4B through 2031 from eased fuel economy rules.
GM faces near-term headwinds from declining vehicle sales and competitive pressure from Asian automakers, but maintains solid cash flow and attractive valuation metrics (P/S 0.42). The stock offers 26% upside to analyst targets, though profitability compression and market share losses present ongoing challenges for investors.
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About General Motors Company
General Motors Co. emerged from the bankruptcy of General Motors Corp. (old GM) in July 2009. GM has eight brands and operates under four segments: GM North America, GM International, Cruise, and GM Financial. The United States now has four brands instead of eight under old GM. The company lost its U.S. market share leader crown in 2021 with share down 280 basis points to 14.6%, but we expect GM to reclaim the top spot in 2022 as 2021 suffered from the chip shortage. GM Financial became the company's captive finance arm in October 2010 via the purchase of AmeriCredit.
Read more on GM →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
